Flatiron Health→Roche
Acquisition · Cash · ROG · announced Jan 8, 2018
Announced
Jan 8, 2018
Closed
Apr 6, 2018
Economics
Cash()
Pre-deal · pre-deal mark: 2018, year precision · rounding grid ±$100M · Roche press release — Flatiron Health acquisition, 2018
~$1.9B fully diluted, subject to adjustments
Target
Flatiron Health
Precision Medicine · Care delivery
HQ New York, NY · Founded 2012
Oncology-specific EHR and real-world evidence platform — 265+ community cancer clinics, data includes breast and ovarian cancer outcomes
- Roche media release (Apr 6, 2018)
- Flatiron Health company website
- Crunchbase - crunchbase.com/organization/flatiron-health
Acquirer
Roche (ROG)
Precision Medicine
HQ Basel, Switzerland
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Oncology-specific EHR and real-world evidence — data from 265+ clinics enables precision medicine research including breast and ovarian cancer treatment outcomes
Evidence ladder
Tertiary (trade / analyst)
Roche media release (Apr 6, 2018)
Limitations
- Single-source or weak corroboration — treat valuation and timing as directional.
- ~$1.9B fully diluted, subject to adjustments
- Pre-deal valuation sourced from: Roche press release — Flatiron Health acquisition, 2018. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Precision Medicine
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Foundation Medicine | Roche | Jun 19, 2018 | same acquirer | |
| Genomic Health | Exact Sciences | Jul 29, 2019 | value band |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Varian Medical Systems | Siemens Healthineers | Aug 2, 2020 | ||
| GRAIL | Illumina | Sep 21, 2020 |
Patient empowerment context
Empowerment context — Flatiron Health
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Presented with clinical trial as treatment option (Company / product site)1 in 5cited HLTH 2022Mapping source →
- No survivorship care plan after active treatment (Company / product site)54%cited HLTH 2022Mapping source →
- Not aware of survivorship resources (Company / product site)2 in 3cited HLTH 2022Mapping source →
Other curated mappings on these gaps: Biotheranostics, Genomic Health, Foundation Medicine, Focal Therapeutics
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 1 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.